Standard BioTools
LAB
104 hedge funds and large institutions have $788M invested in Standard BioTools in 2014 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 41 increasing their positions, 35 reducing their positions, and 26 closing their positions.
131% more call options, than puts
Call options by funds: $23.5M | Put options by funds: $10.2M
17% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 35
3% less funds holding
Funds holding: 107 → 104 (-3)
12% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 26
32% less capital invested
Capital invested by funds: $1.15B → $788M (-$366M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| 1 |
JP Morgan Chase
New York
|
+$38.4M |
| 2 |
O
OrbiMed
New York
|
+$13.3M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$12.6M |
| 4 |
CGI
CI Global Investments
Oakland,
California
|
+$9.61M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$8.59M |
Top Sellers
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$20.6M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$17.4M |
| 3 |
O
OppenheimerFunds
New York
|
-$12.8M |
| 4 |
CCM
Cupps Capital Management
Chicago,
Illinois
|
-$9.64M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$8.81M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PA
126
Perceptive Advisors
New York
| – | -$135K | -3,070 | Closed |
|
|
PSC
127
Piper Sandler & Co
Minneapolis,
Minnesota
| – | -$132K | -3,000 | Closed |
|
|
SFU
128
Stonehage Fleming (UK)
London,
United Kingdom
| – | -$54K | -1,231 | Closed |
|
129
BNP Paribas Financial Markets
Paris,
France
| – | -$2.07K | -55 | Closed |
|
|
GC
130
Globeflex Capital
San Diego,
California
| – | -$1K | -37 | Closed |
|
LAB Hedge Fund Activity: Q2 2014 in Review
104 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q2 2014, worth a combined $788M — down 32% from $1.15B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of LAB and 23 opened new positions — a net loss of 3 holders — while 35 trimmed existing stakes and 41 added.
The largest buyer was JP Morgan Chase, adding an estimated $38.4M. The largest seller was Lord, Abbett & Co, cutting an estimated $20.6M.
- 104 institutional investors held Standard BioTools (LAB) as of Q2 2014, down from 107 in Q1 2014.
- Funds reported $788M of Standard BioTools stock for Q2 2014, down 32% quarter-over-quarter.
- 23 funds opened new Standard BioTools positions in Q2 2014 and 26 closed out, a net change of -3 holders.
- The largest Standard BioTools buyer in Q2 2014 was JP Morgan Chase, an estimated $38.4M added.
- The largest Standard BioTools seller in Q2 2014 was Lord, Abbett & Co, an estimated $20.6M sold.
Based on aggregated 13F filings for Q2 2014.